



November 5, 2012

Merrimack Pharmaceuticals Announces Timing of Third Quarter 2012 Investor Conference Call

CAMBRIDGE, Mass., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Third Quarter 2012 Investor Conference Call and webcast at 11 a.m., Eastern time, on Thursday, November 15.

The call will cover an update on Merrimack's progress as well as a summary of third quarter financials. A press release detailing the information to be discussed on the call will be issued on Wednesday, November 14.

Investors and the general public are invited to listen to the call by dialing (877) 564-1301 (domestic) or (224) 357-2394 (international) five minutes prior to the start of the call and providing the passcode 55448769.

A listen-only webcast of the call can be accessed in the Investor Relations section of Merrimack's website, <http://investors.merrimackpharma.com> and a replay of the call will be archived there.

About Merrimack

Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.

Forward-looking statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

CONTACT: Investor & Media Contact:

Kathleen Petrozzelli Gallagher

Corporate Communications, Merrimack

617-441-1043, kgallagher@merrimackpharma.com

Source: Merrimack Pharmaceuticals

News Provided by Acquire Media